×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ANIP – ani pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ANIP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
7/16
07:00 pm
anip
ANI Pharmaceuticals (ANIP) was given a new $91.00 price target by Canaccord Genuity Group Inc..
Low
Report
ANI Pharmaceuticals (ANIP) was given a new $91.00 price target by Canaccord Genuity Group Inc..
7/16
04:34 pm
anip
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
Medium
Report
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
7/13
07:00 am
anip
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis [Yahoo! Finance]
Low
Report
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis [Yahoo! Finance]
7/13
06:50 am
anip
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
Low
Report
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
7/12
08:47 pm
anip
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run [Yahoo! Finance]
Low
Report
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run [Yahoo! Finance]
7/10
08:45 am
anip
ANI Pharmaceuticals (ANIP) had its "buy" rating reaffirmed by Guggenheim. They now have a $124.00 price target on the stock.
Low
Report
ANI Pharmaceuticals (ANIP) had its "buy" rating reaffirmed by Guggenheim. They now have a $124.00 price target on the stock.
7/9
06:13 pm
anip
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge [Globe and Mail, The (Toronto, Canada)]
Low
Report
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge [Globe and Mail, The (Toronto, Canada)]
7/9
05:59 pm
anip
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge [Yahoo! Finance]
Low
Report
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/27/2026
06:50 am
anip
ani pharmaceuticals, inc.
BEAT
Report
-11.0%
ani pharmaceuticals, inc.
11/7/2025
06:50 am
anip
ani pharmaceuticals, inc.
BEAT
Report
-1.7%
ani pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
7/17
04:23 pm
anip
Form S-8 ANI PHARMACEUTICALS INC
Neutral
Report
Form S-8 ANI PHARMACEUTICALS INC
7/14
04:02 pm
anip
Form 4 ANI PHARMACEUTICALS INC For: Jul 13 Filed by: Cook Meredith
Low
Report
Form 4 ANI PHARMACEUTICALS INC For: Jul 13 Filed by: Cook Meredith
7/7
04:04 pm
anip
Form 144 ANI PHARMACEUTICALS INC Filed by: Walsh Patrick D
Low
Report
Form 144 ANI PHARMACEUTICALS INC Filed by: Walsh Patrick D
7/6
09:40 pm
anip
Form 4 ANI PHARMACEUTICALS INC For: Jul 02 Filed by: CAREY STEPHEN P.
Low
Report
Form 4 ANI PHARMACEUTICALS INC For: Jul 02 Filed by: CAREY STEPHEN P.
6/30
04:15 pm
anip
Form 4 ANI PHARMACEUTICALS INC For: Jun 29 Filed by: CAREY STEPHEN P.
Low
Report
Form 4 ANI PHARMACEUTICALS INC For: Jun 29 Filed by: CAREY STEPHEN P.
6/15
06:44 pm
anip
Form 4 ANI PHARMACEUTICALS INC For: Jun 12 Filed by: Cook Meredith
Low
Report
Form 4 ANI PHARMACEUTICALS INC For: Jun 12 Filed by: Cook Meredith
6/10
09:10 pm
anip
Form 4 ANI PHARMACEUTICALS INC For: May 21 Filed by: Thoma Jeanne
Low
Report
Form 4 ANI PHARMACEUTICALS INC For: May 21 Filed by: Thoma Jeanne
6/10
09:09 pm
anip
Form 4 ANI PHARMACEUTICALS INC For: May 21 Filed by: TANNENBAUM RENEE P
Low
Report
Form 4 ANI PHARMACEUTICALS INC For: May 21 Filed by: TANNENBAUM RENEE P
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
ANI Pharmaceuticals Announces the Filing of a Prior Approval Supplement for Purified Cortrophin® Gel 80 U/mL
18.7%
6/18 ANI Pharmaceuticals Expands Generic Pipeline with Acquisition of Seven Development Stage Drug Products from Coeptis Pharmaceuticals, Inc. 10.0%
4/8 Form 4 ANI PHARMACEUTICALS INC For: Apr 06 Filed by: Schrepfer Robert W 8.0%
4/13 ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin® Gel 80 U/mL 6.1%
9/12 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 5.6%
9/12 ANI Pharmaceuticals Inc (NASDAQ: ANIP) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. 4.1%
1/9 ANI Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd. 3.5%
6/28 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%
5/9 Q1/2019 3/31/2019 EPS 1.300 ZacksConsensus 1.030 ActVsEst 0.270 - Beat 3.1%
10/22 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.0%
6/18 ANI Pharmaceuticals Expands Generic Pipeline with Acquisition of Seven Development Stage Drug Products from Coeptis Pharmaceuticals, Inc. 10.0%
4/8 Form 4 ANI PHARMACEUTICALS INC For: Apr 06 Filed by: Schrepfer Robert W 8.0%
4/13 ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin® Gel 80 U/mL 6.1%
9/12 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 5.6%
9/12 ANI Pharmaceuticals Inc (NASDAQ: ANIP) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. 4.1%
1/9 ANI Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd. 3.5%
6/28 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%
5/9 Q1/2019 3/31/2019 EPS 1.300 ZacksConsensus 1.030 ActVsEst 0.270 - Beat 3.1%
10/22 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.0%
TOP News Decliners
11/6
Q3/2019 9/30/2019 EPS 1.230 ZacksConsensus 1.320 ActVsEst (0.090) - Miss
-23.7%
2/27 Q4/2019 12/31/2019 EPS 1.080 ZacksConsensus 1.020 ActVsEst 0.060 - Beat -18.7%
8/7 Q2/2019 6/30/2019 EPS 1.440 ZacksConsensus 1.180 ActVsEst 0.260 - Beat -15.1%
4/14 ANI Announces Upcoming Departure of CEO -9.0%
3/2 ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules -7.8%
3/4 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.3%
3/7 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.4%
3/31 Form 4 ANI PHARMACEUTICALS INC For: Mar 28 Filed by: PRZYBYL ARTHUR -6.3%
4/14 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -6.0%
1/7 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -5.1%
2/27 Q4/2019 12/31/2019 EPS 1.080 ZacksConsensus 1.020 ActVsEst 0.060 - Beat -18.7%
8/7 Q2/2019 6/30/2019 EPS 1.440 ZacksConsensus 1.180 ActVsEst 0.260 - Beat -15.1%
4/14 ANI Announces Upcoming Departure of CEO -9.0%
3/2 ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules -7.8%
3/4 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.3%
3/7 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.4%
3/31 Form 4 ANI PHARMACEUTICALS INC For: Mar 28 Filed by: PRZYBYL ARTHUR -6.3%
4/14 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -6.0%
1/7 ANI Pharmaceuticals Inc (NASDAQ: ANIP) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -5.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: